Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + Placebo

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Asthma

Conditions

Asthma

Trial Timeline

Apr 15, 2022 → Aug 29, 2023

About Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + Placebo

Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg + Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol + Placebo is a phase 3 stage product being developed by Cipla for Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT05322707. Target conditions include Asthma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05322707Phase 3Completed